Clinical trial
Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or…
NCT00466531 · Memorial Sloan Kettering Cancer Center, Other · Active, not recruiting
Key facts
| NCT number | NCT00466531 |
|---|---|
| Title | Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 |
| Official title | A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Active, not recruiting |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | therapeutic autologous lymphocytes, cyclophosphamide |
| Enrollment | 50 |
| Start date | Mar 21, 2007 |
| Primary completion | Dec 1, 2026 |
| Completion | Dec 1, 2026 |
| First posted | Apr 27, 2007 |
| Last update posted | Apr 10, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: